Companies › Bolt Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BDC-4182 Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist | CLDN18, TLR7, TLR8 | Phase 1 | Gastric Cancer Adenocarcinoma Metastatic | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06921837 | BDC-4182 | Phase 1 | Gastric Cancer Adenocarcinoma Metastatic | Oncology | May 2027 |
Cash and short-term investments of $18m on 2026-06-30; operating cash outflow about $30m a year; runway about 7 months at that burn, to Feb 2027
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Merck KGaA Astellas AstraZeneca Eikon Therapeutics United Immunity Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Inimmune RemeGen
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.